# Thanatophoric Dysplasia Type 1 Treated with Vosoritide: A Case Report.

> PubMed lists PMID 41078071 in Hormone research in paediatrics as Case Reports, Journal Article, with publication-date metadata of 2025-10-10 (day precision). PeptideScanner associated the retained record with the identity slug vosoritide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

- Evidence object: `story:pubmed-pmid-41078071-vosoritide:v1`
- Evidence domain: Literature metadata
- Date in source: 2025-11-21
- Source checked: 2026-07-30
- Published by PeptideScanner: 2026-08-13
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-41078071-vosoritide/
- JSON record: https://peptidescanner.com/evidence/v1/objects/pubmed-pmid-41078071-vosoritide-v1.json
- Content SHA-256: `939aa3ecb07bc9f686e8aac2f85fcf842ad350eb782673b2e2a4e0ba1b912df5`

## Claims and source pins

### Headline

Thanatophoric Dysplasia Type 1 Treated with Vosoritide: A Case Report. ([`pubmed-observation-pmid-41078071-2025-11-21-bdd8317a0587`](#source-pubmed-observation-pmid-41078071-2025-11-21-bdd8317a0587))

### Summary

PubMed lists PMID 41078071 in Hormone research in paediatrics as Case Reports, Journal Article, with publication-date metadata of 2025-10-10 (day precision). PeptideScanner associated the retained record with the identity slug vosoritide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-41078071-2025-11-21-bdd8317a0587`](#source-pubmed-observation-pmid-41078071-2025-11-21-bdd8317a0587))

### Paragraph 1

PubMed lists PMID 41078071 in Hormone research in paediatrics as Case Reports, Journal Article, with publication-date metadata of 2025-10-10 (day precision). PeptideScanner associated the retained record with the identity slug vosoritide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-41078071-2025-11-21-bdd8317a0587`](#source-pubmed-observation-pmid-41078071-2025-11-21-bdd8317a0587))

### Paragraph 2

This page reproduces bounded bibliographic metadata attributed to PubMed. Its title and publication details are source metadata, not PeptideScanner's endorsement or an assertion of safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-41078071-2025-11-21-bdd8317a0587`](#source-pubmed-observation-pmid-41078071-2025-11-21-bdd8317a0587))

## Sources

<a id="source-pubmed-observation-pmid-41078071-2025-11-21-bdd8317a0587"></a>
- **Thanatophoric Dysplasia Type 1 Treated with Vosoritide: A Case Report. · retained source version 1:2025-11-21:current:bdd8317a058752ace60dd5def00e9684f8974b5db82671dcc639eec3b6437a78** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/41078071/) (`pubmed-observation-pmid-41078071-2025-11-21-bdd8317a0587`)

## Correction lineage

No correction is recorded for this version.

## Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

## Suggested citation

PeptideScanner. "Thanatophoric Dysplasia Type 1 Treated with Vosoritide: A Case Report." Version 1, published 2026-08-13. https://peptidescanner.com/evidence/v1/objects/pubmed-pmid-41078071-vosoritide-v1.json SHA-256: 939aa3ecb07bc9f686e8aac2f85fcf842ad350eb782673b2e2a4e0ba1b912df5.